A comparative study of short- and long-TE 1H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors

NMR in Biomedicine

Volumn 26, Issue 10, 2013, Pages 1242-1250

  Choi, Changho ^a,b,c   Ganji, Sandeep ^a,b   Hulsey, Keith ^a   Madan, Akshay ^a   Kovacs, Zoltan ^a   Dimitrov, Ivan ^a,d   Zhang, Song ^a   Pichumani, Kumar ^a   Mendelsohn, Dianne ^b   Mickey, Bruce ^a,b,c   Malloy, Craig ^a,b,e   Bachoo, Robert ^a,b,c   Deberardinis, Ralph ^a   Maher, Elizabeth ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d PHILIPS HEALTHCARE   (United States)

^e VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

2 hydroxyglutarate (2HG); 3 T; 1H MRS; Human brain; IDH mutated gliomas; Point resolved spectroscopy (PRESS); Short long TE; Volume localized simulations

Indexed keywords

2-HYDROXYGLUTARATE (2HG); 3 T; 1H MRS; HUMAN BRAIN; IDH-MUTATED GLIOMAS; POINT-RESOLVED SPECTROSCOPY (PRESS); VOLUME-LOCALIZED SIMULATIONS;

BRAIN;

TUMORS;

2 HYDROXYGLUTARIC ACID; 4 AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; ISOCITRATE DEHYDROGENASE;

ADULT; ARTICLE; ASTROCYTOMA; BRAIN METABOLISM; BRAIN TUMOR; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; GLIOBLASTOMA; GLIOMA; HUMAN; IN VIVO STUDY; METABOLITE; MUTATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PHANTOM; POINT RESOLVED SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT RESPONSE; TUMOR DIAGNOSIS; TUMOR GROWTH;

1H MRS; 2-HYDROXYGLUTARATE (2HG); 3 T; HUMAN BRAIN; IDH-MUTATED GLIOMAS; POINT-RESOLVED SPECTROSCOPY (PRESS); SHORT/LONG TE; VOLUME-LOCALIZED SIMULATIONS;

ADULT; ASPARTIC ACID; BRAIN NEOPLASMS; GAMMA-AMINOBUTYRIC ACID; GLIOMA; GLUTAMIC ACID; GLUTAMINE; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; MUTATION; PHANTOMS, IMAGING; PROTONS; YOUNG ADULT;

EID: 84883791715     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2943     Document Type: Article

References (31)

1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
2. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009; 360: 765-773.
3. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744.
4. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
5. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
6. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-478.
7. 13C NMR study of 2-hydroxyglutaric acid and its lactone. Magn. Reson. Chem. 2002; 40: 533-536.
8. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000; 13: 129-153.
9. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J. Neurooncol 2012; 107: 197-205.
10. Choi C, Ganji SK, Deberardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen JM, Marin-Valencia I, Pascual JM, Madden CJ, Mickey BE, Malloy CR, Bachoo RM, Maher EA. 2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 2012; 18: 624-629.
11. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci. Transl. Med. 2012; 4: 116ra114.
12. Slotboom J, Mehlkope AF, Bovee WMMJ. The effects of frequency-selective RF pulses on J-coupled spin-1/2 systems. J. Magn. Reson. A 1994; 108: 38-50.
13. Thompson RB, Allen PS. Sources of variability in the response of coupled spins to the PRESS sequence and their potential impact on metabolite quantification. Magn. Reson. Med. 1999; 41: 1162-1169.
14. 1H MR spectroscopy. J. Magn. Reson. 2008; 195: 67-75.
15. 1H-MRSI of the human brain at 7 T with minimal signal loss. NMR Biomed. 2009; 22: 683-696.
16. Barker PB, Bizzi A, De Stefano N, Gullapalli RP, Lin DDM. Clinical MR Spectroscopy: Techniques and Applications. Cambridge University Press: Cambridge; 2010.
17. Mullins PG, Chen H, Xu J, Caprihan A, Gasparovic C. Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn. Reson. Med. 2008; 60: 964-969.
18. Gruetter R. Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn. Reson. Med. 1993; 29: 804-811.
19. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn. Reson. Med. 1990; 14: 26-30.
20. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993; 30: 672-679.
21. 2 relaxation times of human brain metabolites at 3 Tesla. NMR Biomed. 2001; 14: 325-331.
22. 2 values in normal brain and determination of regional differences in transverse relaxation. J. Magn. Reson. Imaging 2004; 19: 537-545.
23. 2 measurement of J-coupled metabolites in the human brain at 3 T. NMR Biomed. 2012; 25: 523-529.
24. Edden RA, Barker PB. If J doesn't evolve, it won't J-resolve: J-PRESS with bandwidth-limited refocusing pulses. Magn. Reson. Med. 2011; 65: 1509-1514.
25. Popovici-Muller J, Saunders JO, Salituro FG, Travins JM, Yan S, Zhao F, Gross S, Dang L, Yen KE, Yang H, Straley KS, Jin S, Kunii K, Fantin VR, Zhang S, Pan Q, Shi D, Biller SA, Su SM. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med. Chem. Lett. 2012; 3: 850-855.
26. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, Rajagopalan KN, Maddie M, Vemireddy V, Zhao Z, Cai L, Good L, Tu BP, Hatanpaa KJ, Mickey BE, Mates JM, Pascual JM, Maher EA, Malloy CR, Deberardinis RJ, Bachoo RM. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012; 15: 827-837.
27. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, Bourne G, Berger MS, Chang SM, Cha S, Nelson SJ. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci. Transl. Med. 2012; 4: 116ra115.
28. 1H MR spectroscopy for clinical use. Prog. Nucl. Magn. Reson. Spec. 1997; 31: 155-195.
29. Keevil SF, Barbiroli B, Brooks JC, Cady EB, Canese R, Carlier P, Collins DJ, Gilligan P, Gobbi G, Hennig J, Kugel H, Leach MO, Metzler D, Mlynarik V, Moser E, Newbold MC, Payne GS, Ring P, Roberts JN, Rowland IJ, Thiel T, Tkac I, Topp S, Wittsack HJ, Wylezinska M, Zaniol P, Henriksen O, Podo F. Absolute metabolite quantification by in vivo NMR spectroscopy: II. A multicentre trial of protocols for in vivo localised proton studies of human brain. Magn. Reson. Imaging 1998; 16: 1093-1106.
30. Martinez-Bisbal MC, Monleon D, Assemat O, Piotto M, Piquer J, Llacer JL, Celda B. Determination of metabolite concentrations in human brain tumour biopsy samples using HR-MAS and ERETIC measurements. NMR Biomed. 2009; 22: 199-206.
31. Tong Z, Yamaki T, Harada K, Houkin K. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. Magn. Reson. Imaging 2004; 22: 1017-1024.